FGF19 and cholestasis: This combined treatment was highly effective in alleviating cholangiopathy and portal fibrosis in the female Cyp2c70 KO mice, suggesting that combining ASBT inhibitor and FGF19 analogue could provide improved therapeutic efficacy in certain forms of cholestasis that could theoretically benefit from a much higher degree of bile acid pool reduction.